1997.-The cessation of firing of serotonergic dorsal raphe neurons is a key controlling event of rapid eye movement (REM) sleep. We tested the hypothesis that this cessation of activity is due to y-aminobutyric acid (GABA) release using the in vivo microdialysis technique.
We found that REM sleep is accompanied by a selective increase in GABA release, but not by a change in glutamate or glycine release in the dorsal raphe nucleus. Microinjection of the GABA agonist muscimol into the dorsal raphe increased REM sleep, although microperfusion of the GABA antagonist picrotoxin blocked REM sleep. These results implicate GABA release as a critical element in the production of the REM sleep state and in the control of discharge in serotonergic neurons across the sleep/wake cycle. microdialysis; muscimol; picrotoxin; serotonin THE SEROTONERGIC NEURONS of the brain stem dorsal raphe (DR) nucleus innervate multiple neocortical, hippocampal, diencephalic, and brain stem regions of the mammalian brain (3, 33, 37, 43) . The activity of serotonergic neurons has been implicated in the control of shifts between states of sleep, nociception, cortical desynchronization, and normal and abnormal emotional states (38, 42) . The greatest change in the discharge rate of DR cells occurs across the sleep/wake cycle. In the freely behaving cat, serotonergic neurons fire tonically at a rate of 3-6 Hz throughout waking and at l-2 Hz during slow-wave sleep (SWS). During rapid eye movement (REM) sleep, serotonergic neurons exhibit a near-complete cessation of activity (23,25). The decreased activity of serotonergic neurons during REM sleep is accompanied by a decrease in serotonin release in several brain areas implicated in the production of sleep including the hypothalamus and pontine reticular formation (PRF) (15, 28, 44) . Evidence from several laboratories suggests that the inactivity of DR serotonergic neurons disinhibits neuronal mechanisms responsible for the production of REM sleep. Thus blockade of DR neuronal activity by local cooling has been shown to induce REM sleep (6), and electrical stimulation of the DR blocks REM sleep (5). An increase in REM sleep time occurs with continuous perfusion of the DR with %hydroxy-2(di-n-propylamino)-tetralin, a compound that inhibits the activity of DR serotonergic cells by activation of 5hydroxytryptamine la (5-HT1,) autoreceptors (29). The cessation of activity of serotonergic neurons is required for the generation of ponto-geniculo-occipital (PGO) spikes, a key phasic event of REM sleep (6, 18, 36) . Recent evidence suggests that serotonin modulates the production of PGO spikes through actions in the amygdala (32) as well as through inhibition of brain stem cholinergic neurons, which are known to fire in conjunction with PGO waves (20, 22, 39) .
The neurochemical mechanism underlying the cessation of DR serotonergic unit activity during REM sleep is unknown. It is unlikely that serotonergic inhibition of DR serotonergic cells through an autoreceptor mechanism is responsible, because the concentration of serotonin in the DR is lowest during REM sleep (28). In addition, data suggest that autoinhibitory mechanisms of serotonergic DR cells are significantly activated only during waking behaviors (8). Disfacilitation by removal of an excitatory noradrenergic or glutamatergic input could contribute to reduced discharge of DR units during sleep. However, serotonergic DR neurons exhibit pacemaker potentials in the anesthetized rat (1) and are unresponsive to excitatory input during REM sleep (23). Therefore, we hypothesized that the cessation of activity in serotonergic DR neurons during REM sleep is mediated by active inhibition.
Both y-aminobutyric acid (GABA) and glycine potently inhibit serotonergic DR neurons (10, 11, 26) . GABAergic and glycinergic neurons densely innervate the serotonergic neurons of the DR (9,12). A glycinergic mechanism mediates the characteristic muscle atonia of REM sleep through active inhibition of spinal motoneurons (7). We hypothesized that GABA and/or glycine are selectively released on serotonergic neurons during REM sleep. We tested this hypothesis by developing techniques for the measurement of GABA and glycine release in the DR across sleep/wake states with in vivo microdialysis and high-performance liquid chromatography (HPLC). over a 2-h period (t-test, n = 4, P c 0.03) (Fig. 3 ).
METHODS
Increases in REM sleep time were offset by decreases in SWS and wake time that were not statistically significant. REM sleep amounts returned to control levels during hours 3-6 of the recording period.
Microperfusion of the DR area with the GABAA receptor Cl-channel blocker picrotoxin (0.1 mM) via a microdialysis probe completely blocked the production of REM sleep over a 4-h period in two animals and decreased REM sleep time by 83% in a third (t-test, n = 3, P < 0.05) (Fig. 4) . In each case, the animals were able to initiate and maintain normal periods of SWS and wake. No significant differences in SWS or wake amounts were observed.
DISCUSSION
The finding of increased GABA in the DR during REM sleep is consistent with the hypothesis that GABA mediates active inhibition of DR serotonergic neurons during REM sleep. We also examined the efficacy and necessity of GABAergic input to the DR for REM sleep control. The large reduction in REM sleep amounts during picrotoxin perfusion in the DR indicates that the inhibition of DR serotonergic neurons by GABAA receptor activation is required for the production of REM sleen. Increases in REM sleen time after the ajpregu.physiology.org Downloaded from microinjection of the GABA* receptor agonist muscimol are consistent with our hypothesis that the inhibition of DR serotonergic cells by a GABAergic mechanism is permissive to and facilitates REM sleep production.
Our microdialysis data suggest that GABAergic neurons, within or projecting to the DR, are selectively active during REM sleep. The location of neurons mediating the increased GABA release in the DR during REM sleep remains undetermined.
Both intrinsic and extrinsic sources of GABA innervation in the DR nucleus are possible origins of state-dependent GABA release. Fos immunolabeling indicates that small, nonserotonergic, possibly GABAergic, neurons of the DR are activated after the induction of a REM sleeplike state with microinjection of carbachol in the PRF (34,45). Aghajanian et al. (2) identified a population of nonserotonergic cells in the dorsal raphe that exhibited changes in firing opposite that of serotonergic cells in response to peripheral nerve stimulation. However, unit recording studies of the DR have not revealed units whose activity across the sleep/wake cycle parallel the changes we observed in GABA release. Thus GABA release selective to REM sleep could arise from small DR neurons not easily recorded with conventional extracellular recording techniques or from neurons external to the DR. There are GABAergic projections to the DR from the preoptic and posterior hypothalamus, the periaqueductal gray, the midbrain and PRF, the peribrachial region, and the prepositus hypoglossal nucleus (9,12). It is likely that the source of state-dependent GABA release in the DR is caudal to the midbrain because DR units have been demonstrated to retain their REM-off pattern of firing in decerebrate cats (14) .
Neurons discharging selectively during REM sleep have been identified in the dorsolateral PRF (35). A population of GABAergic cells has been identified in this same region (17). The dorsolateral PRF sends projections to the DR, some of which are GABAergic (4, 27) . Together with the GABA release data presented herein, these findings suggest that some PRF REM-on neurons may be GABAergic.
REM sleep behavior disorder in humans is characterized by fragmented REM sleep as well as a disruption of muscle atonia within REM sleep (24). It resembles a syndrome seen after lesions of the dorsolateral pons in the cat (13, 18) . In contrast to normal REM sleep, serotonergic neurons are not completely silent during REM sleep in the REM sleep without atonia syndrome (40). REM sleep behavior disorder is successfully treated with clonazepam, a benzodiazepine that potentiates GABAA receptors and has been shown to decrease the use of serotonin in the mouse brain (30). This suggests that a disruption of the output of GABAergic PRF neurons projecting to the raphe nuclei could underlie this disorder of REM sleep.
Microiontophoretic application of the GABAA receptor antagonist bicuculline (Bit) reduces the decrease in DR unit discharge in SWS but not in REM sleep (21). We found no significant increase in GABA release in SWS. However, a small increase in the release of GABA, possibly beyond the resolution of the microdialysis technique, might be sufficient to reduce DR unit discharge in SWS. This interpretation is consistent with the report by Lydic et al. (23) indicating greatly decreased response of DR cells to excitatory input in REM sleep compared with SWS, despite a relatively small decrease in discharge rate from SWS to REM sleep. Greatly increased levels of GABA release would not be reflected in DR unit discharge because DR discharge in REM sleep falls to zero from the already minimal SWS rates. Our microdialysis and microperfusion data provide strong evidence that GABA mediates the suppression of serotonergic unit discharge during REM sleep. Indeed, as suggested by Levine and Jacobs (21), the inability of iontophoresed Bit to reverse REM sleep cessation of DR unit discharge could be due to incomplete antagonism of DR GABAA receptors as a result of increased GABA release. The results of the present study are compatible with their hypothesis. This interpretation is also consistent with the blockade of REM sleep production that we observed with picrotoxin perfusion. The antagonism of GABAergic activity in the DR by picrotoxin would not be blocked by increased GABA concentration because picrotoxin acts at the GABAA receptor Cl-channel rather than competing with GABA at the GABAA receptor binding site, as is the case for Bit (19).
In summary, we have demonstrated that GABA release in the DR is increased during REM sleep. Alterations in the production of REM sleep after the microinjection of a GABAA receptor agonist and antagonist into the DR are consistent with the hypothesis that inhibition of serotonergic DR neurons by a GABAergic mechanism is a key controlling event of REM sleep. Our findings suggest that a group of REM-on neurons responsible for initiating REM sleep is GABAergic. 
